Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PGR | P06401 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bolenol SCHEMBL636530 | 1.00 | ESR1 (0.71) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL11217999 | 0.83 | SLC6A4 (1.00) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL147908 | 0.83 | SLC6A4 (1.00) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Cingestol SCHEMBL282508 | 0.82 | CYP3A4 (0.72) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Cingestol SCHEMBL12178106 | 0.82 | CYP3A4 (0.72) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL28817294 | 0.79 | SLC6A4 (0.89) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| Ethylestrenol SCHEMBL5491436 | 0.78 | SLC6A4 (0.88) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| SCHEMBL11517786 | 0.75 | ESR1 (0.55) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| SCHEMBL5799984 | 0.75 | CYP19A1 (0.58) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 | |
| SCHEMBL2507306 | 0.73 | CYP19A1 (0.40) | ESR1SLC6A4CYP2C19CHRM2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2011-01-06 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| EP-2077844-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | Jennings-Spring, Barbara L. (US) | 2009-07-15 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| WO-2008066634-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | JENNINGS-SPRING BARBARA L (US) | 2008-06-05 | — | — | WO | claimed |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2008-05-01 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | ESR1 468/4885SLC6A4 3578/4885CYP2C19 4329/4885 |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | PGF, ERH, BRCA1 | ESR1 1205/4885SLC6A4 3255/4885CYP2C19 4420/4885 |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | ESR1 468/4885SLC6A4 3578/4885CYP2C19 4329/4885 |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | SHH, ERH, CDK5 | ESR1 903/4885SLC6A4 2081/4885CYP2C19 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.